Maiden interims are in line with expectations, mainly reflecting the company’s successful IPO on AIM in November 2018. The development of KidneyIntelX™ (AI-enabled diagnostic for the detection of fast-progressing Chronic Kidney Disease, CKD) is progressing strongly, with results from the ongoing 5,000-patient validation study expected in mid2019. We continue to believe that Renalytix AI is well placed to deliver high returns in the large CKD market, and reiterate our highly positive stance. As a ....
27 Mar 2019
Maiden interims in line: KidneyIntelX™ validation study data mid-2019e
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Maiden interims in line: KidneyIntelX™ validation study data mid-2019e
Renalytix Plc (RENX:LON) | 26.5 0 0.0% | Mkt Cap: 33.4m
- Published:
27 Mar 2019 -
Author:
Jens Lindqvist -
Pages:
3
Maiden interims are in line with expectations, mainly reflecting the company’s successful IPO on AIM in November 2018. The development of KidneyIntelX™ (AI-enabled diagnostic for the detection of fast-progressing Chronic Kidney Disease, CKD) is progressing strongly, with results from the ongoing 5,000-patient validation study expected in mid2019. We continue to believe that Renalytix AI is well placed to deliver high returns in the large CKD market, and reiterate our highly positive stance. As a ....